Back to top
more

Immunocore (IMCR)

(Delayed Data from NSDQ)

$38.91 USD

38.91
280,508

-0.71 (-1.79%)

Updated Aug 2, 2024 04:00 PM ET

After-Market: $39.00 +0.09 (0.23%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Wall Street Analysts Believe Immunocore Holdings PLC Sponsored ADR (IMCR) Could Rally 60%: Here's is How to Trade

by Zacks Equity Research

The consensus price target hints at a 60.4% upside potential for Immunocore Holdings PLC Sponsored ADR (IMCR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Avidity (RNA) Down on Partial Hold of Myotonic Dystrophy Study

by Zacks Equity Research

Avidity Biosciences (RNA) reports FDA-imposed partial hold on enrolling new patients in its phase I/II MARINA study evaluating AOC 1001 in myotonic dystrophy type 1 in adults. Stock down.

Bellerophon (BLPH) Receives FDA Acceptance to Reduce Study Size

by Zacks Equity Research

Bellerophon's (BLPH) proposal to reduce the size of its ongoing phase III REBUILD study of INOpulse in fibrotic Interstitial Lung Disease gets accepted by the FDA. Stock up.

Ekta Bagri headshot

Bet on These 4 Biotech Stocks With Bright Prospects

by Ekta Bagri

New drug approvals and pipeline development should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position AGEN, CVAC, IMCR and DVAX well amid the volatility.

9 Meters (NMTR) Up on Results From Bowel Syndrome Candidate

by Zacks Equity Research

9 Meters (NMTR) reports a positive top line from a phase II study of vurolenatide, being evaluated for short bowel syndrome in adults and a successful end-of-phase II meeting with the FDA.

DBV Technologies' (DBVT) Peanut Allergy Study on Partial Hold

by Zacks Equity Research

DBV Technologies (DVBT) announces partial hold on phase III study of modified Viaskin Peanut 250 ??g patch, VITESSE, by the FDA. Stock declines.

Is Immunocore (IMCR) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Immunocore Holdings PLC Sponsored ADR (IMCR) and vTv Therapeutics (VTVT) have performed compared to their sector so far this year.

Regeneron (REGN)/ Alnylam Report Promising Data from NASH Study

by Zacks Equity Research

Regeneron (REGN) and its partner Alnylam announce promising data from its ongoing phase I study evaluating ALN-HSD in healthy adults and NASH patients.

Akero Therapeutics (AKRO) Up on Positive Data from NASH Study

by Zacks Equity Research

Akero Therapeutics (AKRO) reports positive top-line data from a mid-stage study evaluating its lead candidate, efruxifermin (EFX), in patients with NASH, fibrosis stage 2 or 3 (F2-F3). Stock up.

    Syros (SYRS) Up on FDA's Orphan Tag for Pancreatic Cancer Drug

    by Zacks Equity Research

    Syros Pharmaceuticals (SYRS) receives Orphan Drug designation from the FDA for its pipeline candidate AY-5609 being developed for treating metastatic pancreatic cancer. Stock up.

    Ideaya (IDYA) Up on Interim Data from Mid-Stage Eye Cancer Study

    by Zacks Equity Research

    Ideaya Biosciences (IDYA) reports positive interim results from its mid-stage study, evaluating darovasertib in combination with Pfizer's Xalkori (crizotinib) in metastatic uveal melanoma. Stock up.

    Axsome (AXSM) Initiates Late-Stage Alzheimer's Agitation Study

    by Zacks Equity Research

    Axsome Therapeutics (AXSM) enrolls the first patient in a late-stage study of AXS-05 for Alzheimer's disease agitation.

    Is Argenx (ARGX) Stock Outpacing Its Medical Peers This Year?

    by Zacks Equity Research

    Here is how argenex SE (ARGX) and Immunocore Holdings PLC Sponsored ADR (IMCR) have performed compared to their sector so far this year.

    Axsome (AXSM) Starts Late-Stage Study of Migraine Drug AXS-07

    by Zacks Equity Research

    Axsome (AXSM) initiates a phase III open-label study for its pipeline candidate, AXS-07 for treating acute migraine.

    Pliant (PLRX) Receives Positive Review of IPF Study at Top Dose

    by Zacks Equity Research

    Pliant (PLRX) receives a positive DSMB review of the ongoing mid-stage study evaluating the company's lead candidate PLN-74809 for treating idiopathic pulmonary fibrosis.

    Sorrento (SRNE) Gets FDA Fast Track Tag for Back Pain Product

    by Zacks Equity Research

    Sorrento Therapeutics' (SRNE) subsidiary Scilex receives Fast Track designation for its lower back pain (LBP) candidate, SP-103. Stock Up.

    Does Immunocore Holdings PLC Sponsored ADR (IMCR) Have the Potential to Rally 45% as Wall Street Analysts Expect?

    by Zacks Equity Research

    The consensus price target hints at a 44.9% upside potential for Immunocore Holdings PLC Sponsored ADR (IMCR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

    Here's Why Momentum in Immunocore Holdings PLC Sponsored ADR (IMCR) Should Keep going

    by Zacks Equity Research

    Immunocore Holdings PLC Sponsored ADR (IMCR) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

    What Makes Immunocore Holdings PLC Sponsored ADR (IMCR) a Strong Momentum Stock: Buy Now?

    by Zacks Equity Research

    Does Immunocore Holdings PLC Sponsored ADR (IMCR) have what it takes to be a top stock pick for momentum investors? Let's find out.

    Is Immunocore (IMCR) Stock Outpacing Its Medical Peers This Year?

    by Zacks Equity Research

    Here is how Immunocore Holdings PLC Sponsored ADR (IMCR) and Bellicum Pharmaceuticals (BLCM) have performed compared to their sector so far this year.

    Wall Street Analysts Think Immunocore Holdings PLC Sponsored ADR (IMCR) Could Surge 32%: Read This Before Placing a Bet

    by Zacks Equity Research

    The consensus price target hints at a 31.8% upside potential for Immunocore Holdings PLC Sponsored ADR (IMCR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

    Here's Why "Trend" Investors Would Love Betting on Immunocore Holdings PLC Sponsored ADR (IMCR)

    by Zacks Equity Research

    Immunocore Holdings PLC Sponsored ADR (IMCR) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

    Is Immunocore (IMCR) Outperforming Other Medical Stocks This Year?

    by Zacks Equity Research

    Here is how Immunocore Holdings PLC Sponsored ADR (IMCR) and Jazz Pharmaceuticals (JAZZ) have performed compared to their sector so far this year.

    Zacks.com featured highlights Immunocore Holdings, Franklin Covey, Ardmore Shipping, StoneX and Alliance Resource

    by Zacks Equity Research

    Immunocore Holdings, Franklin Covey, Ardmore Shipping, StoneX and Alliance Resource have been highlighted in this Screen of The Week article.

    Here's What Could Help Immunocore Holdings PLC Sponsored ADR (IMCR) Maintain Its Recent Price Strength

    by Zacks Equity Research

    Immunocore Holdings PLC Sponsored ADR (IMCR) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.